JTA-004 is under clinical development by BioSenic and currently in Phase III for Osteoarthritis. According to GlobalData, Phase III drugs for Osteoarthritis does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the JTA-004 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JTA-004 overview
JTA-004 is under development for the treatment of knee osteoarthritis and osteoarthritis pain. The drug candidate is a mixture of plasma proteins, hyaluronic acid and clonidine. It is administered through intraarticular route. The therapeutic candidate constitutes treated plasma acting as viscosupplement. It is developed using JTA technology
BioSenic overview
BioSenic, formerly Bone Therapeutics, is a pharmaceutical company. It develops cell therapy products for orthopedics and bone diseases. The company’s major pipeline products such as ALLOB, an allogeneic osteoblastic cell therapy product, for delayed-union fractures, spinal fusion procedures, revision spinal fusion, JTA-004; for the treatment of knee osteoarthritis, BT-20 for the treatment of inflammation, BT-XX for other treatments. BioSenic conducts preclinical research on next generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications. The company conducts clinical studies for treatment of delayed-union fractures and spinal fusion. BioSenic is headquartered in Guibert, Belgium.
For a complete picture of JTA-004’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
